title: Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine.
abstract: We reviewed clinical evidence for the use of ivabradine in systolic heart failure (HF), in which it appears to improve symptoms, improve quality of life, prevent hospitalization, and prolong survival, thereby addressing unmet needs in the management of HF. Ivabradine provides symptomatic benefits in HF on top of standard therapies, in terms of functional parameters and exercise capacity, and there is some evidence that this leads to improvements in quality of life in symptomatic HF patients, who may have dyspnea, altered exercise capacity, and fatigue. The SHIFT trial demonstrated that ivabradine has significant beneficial effects on major outcomes in HF. Ivabradine had a significant effect on pump failure death, which was reduced by 26 % (p = 0.014), with no effect on sudden cardiac death. This is an important result since pump failure death is currently the main cause of death in HF, and also because the reductions in mortality obtained with beta-blockers and spironolactone in the last 20 years appear to be mainly due to reduction in sudden death rather than reduction in pump failure death. Ivabradine also has a beneficial effect on hospital admissions (-26 %, p < 0.0001), which is clinically relevant since a quarter of HF patients can expect to be readmitted to hospital for HF within 1 month of discharge. Ivabradine-treated patients are also at significantly lower risk of experiencing a second or third hospitalization for worsening HF. Ivabradine clearly has a key role to play in the management of HF by covering the main therapeutic objectives of symptoms, quality of life, and outcomes.
authors.affiliation: Prevention and Rehabilitation Service, Heart Institute (InCor), University of São Paulo Medical School, Av Dr Enéas de Carvalho Aguiar, 44, São Paulo, SP, CEP 05403-900, Brazil. antonio.barretto@incor.usp.br.
authors.forename: Antonio Carlos
authors.initials: AC
authors.lastname: Pereira-Barretto
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D054143:Heart Failure, Systolic / Q000188:drug therapy*; D006760:Hospitalization; D006801:Humans; D000077550:Ivabradine; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D001552:Benzazepines; D002317:Cardiovascular Agents; D000077550:Ivabradine
references.citation: Eur J Heart Fail. 2002 Jun;4(3):361-71
references.pmid: 12034163
references.citation: Am J Cardiovasc Drugs. 2015 Dec;15(6):387-93
references.pmid: 26239259
references.citation: BMC Cardiovasc Disord. 2013 Jul 13;13:52
references.pmid: 23848972
references.citation: Eur J Heart Fail. 2012 Mar;14(3):234-9
references.pmid: 22237388
references.citation: Arch Cardiovasc Dis. 2013 Nov;106(11):570-85
references.pmid: 24140417
references.citation: Circulation. 2009 Feb 3;119(4):515-23
references.pmid: 19153268
references.citation: Am Heart J. 2010 May;159(5):841-849.e1
references.pmid: 20435194
references.citation: BMC Cancer. 2010 Mar 22;10:105
references.pmid: 20307299
references.citation: N Engl J Med. 2002 Oct 31;347(18):1397-402
references.pmid: 12409541
references.citation: J Card Fail. 2008 Apr;14(3):211-8
references.pmid: 18381184
references.citation: J Am Coll Cardiol. 2013 Nov 19;62(21):1977-1985
references.pmid: 23933545
references.citation: Eur J Heart Fail. 2008 Nov;10(11):1108-16
references.pmid: 18838295
references.citation: Int J Cardiol. 2001 Feb;77(2-3):239-45
references.pmid: 11182188
references.citation: Am J Cardiovasc Drugs. 2014 Jun;14(3):229-35
references.pmid: 24452599
references.citation: Eur J Heart Fail. 2013 Jan;15(1):79-84
references.pmid: 22892123
references.citation: JACC Heart Fail. 2013 Feb;1(1):1-20
references.pmid: 24621794
references.citation: Adv Ther. 2015 Oct;32(10):906-19
references.pmid: 26521191
references.citation: Circulation. 2012 Jan 3;125(1):e2-e220
references.pmid: 22179539
references.citation: Int J Cardiol. 2011 Feb 3;146(3):408-14
references.pmid: 21112101
references.citation: JAMA. 2011 Oct 19;306(15):1669-78
references.pmid: 22009099
references.citation: N Engl J Med. 1991 Aug 1;325(5):293-302
references.pmid: 2057034
references.citation: BMJ. 2013 Jan 16;346:f55
references.pmid: 23325883
references.citation: Eur J Heart Fail. 2012 Aug;14(8):803-69
references.pmid: 22828712
references.citation: JACC Heart Fail. 2015 Mar;3(3):268-9
references.pmid: 25742766
references.citation: J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):349-55
references.pmid: 20940450
references.citation: J Am Coll Cardiol. 1998 Dec;32(7):1811-8
references.pmid: 9857856
references.citation: Pharmacology. 2013;92(5-6):276-80
references.pmid: 24296869
references.citation: Indian Pacing Electrophysiol J. 2011 Sep;11(5):149-52
references.pmid: 21994473
references.citation: Eur J Heart Fail. 2004 Jun;6(4):467-75
references.pmid: 15182773
references.citation: Eur Heart J. 2003 Mar;24(5):464-74
references.pmid: 12633547
references.citation: Int J Cardiol. 2014 Feb 15;171(3):368-76
references.pmid: 24398230
references.citation: Age Ageing. 2006 Mar;35(2):172-7
references.pmid: 16495294
references.citation: Eur Heart J. 2005 Apr;26(8):778-93
references.pmid: 15774495
references.citation: J Am Coll Cardiol. 2005 Dec 20;46(12):2329-34
references.pmid: 16360067
references.citation: Lancet. 2010 Sep 11;376(9744):875-85
references.pmid: 20801500
references.citation: Cardiovasc Ther. 2015 Jun;33(3):104-8
references.pmid: 25809454
references.citation: J Am Coll Cardiol. 2012 May 29;59(22):1938-45
references.pmid: 22617188
references.citation: Cardiology. 2015;131(4):218-24
references.pmid: 25968495
references.citation: Eur Heart J. 2005 Dec;26(23):2529-36
references.pmid: 16214830
references.citation: Eur J Heart Fail. 2015 Dec;17(12):1294-301
references.pmid: 26377342
references.citation: Eur Heart J. 2012 Nov;33(22):2813-20
references.pmid: 22927555
references.citation: Case Rep Med. 2011;2011:203690
references.pmid: 21966292
references.citation: N Engl J Med. 2014 Sep 18;371(12):1091-9
references.pmid: 25176136
references.citation: Eur J Heart Fail. 2013 Nov;15(11):1296-303
references.pmid: 23803951
references.citation: Eur J Heart Fail. 2014 Jul;16(7):810-6
references.pmid: 24961493
references.citation: Cleve Clin J Med. 2010 Jul;77 Suppl 3:S7-S11
references.pmid: 20622081
references.citation: Curr Med Res Opin. 2015;31(10):1903-9
references.pmid: 26361063
references.citation: Am Heart J. 2008 Sep;156(3):422-30
references.pmid: 18760121
references.citation: Int J Environ Res Public Health. 2010 Apr;7(4):1807-30
references.pmid: 20617060
references.citation: Am Heart J. 2007 Aug;154(2):260-6
references.pmid: 17643574
references.citation: Lancet. 2008 Sep 6;372(9641):807-16
references.pmid: 18757088
references.citation: Eur Heart J. 2009 Mar;30(5):540-8
references.pmid: 19136486
references.citation: Am J Med. 2003 Jun 1;114(8):625-30
references.pmid: 12798449
references.citation: Am J Crit Care. 2008 Mar;17(2):124-32
references.pmid: 18310649
references.citation: Pharmacoeconomics. 2008;26(6):447-62
references.pmid: 18489197
references.citation: Arq Bras Cardiol. 2012 Jan;98(1 Suppl 1):1-33
references.pmid: 22392082
references.citation: Gen Pharmacol. 1998 Jul;31(1):93-9
references.pmid: 9595286
references.citation: Am J Cardiol. 2005 Sep 19;96(6A):11G-17G
references.pmid: 16196154
references.citation: Circulation. 2003 Feb 18;107(6):817-23
references.pmid: 12591750
references.citation: Lancet. 1999 Jun 12;353(9169):2001-7
references.pmid: 10376614
references.citation: Clin Res Cardiol. 2009 Aug;98(8):513-5
references.pmid: 19547907
references.citation: Int J Cardiol. 2008 Aug 1;128(1):22-9
references.pmid: 18258318
references.citation: Circ Heart Fail. 2013 May;6(3):411-9
references.pmid: 23479563
references.citation: Int J Cardiol. 2013 Dec 10;170(2):182-8
references.pmid: 24225201
references.citation: Lancet. 1997 Feb 8;349(9049):375-80
references.pmid: 9033462
references.citation: Int J Cardiol. 2011 Sep 1;151(2):218-24
references.pmid: 21764469
references.citation: Eur Heart J. 2015 Dec 7;36(46):3291-6
references.pmid: 26385957
references.citation: Lancet. 1999 Jan 2;353(9146):9-13
references.pmid: 10023943
references.citation: Mem Inst Oswaldo Cruz. 2007 Oct 30;102 Suppl 1:75-85
references.pmid: 17891282
references.citation: J Card Fail. 2014 Oct;20(10):723-730
references.pmid: 25079300
references.citation: JAMA. 2013 Jan 23;309(4):355-63
references.pmid: 23340637
references.citation: Eur Heart J. 2011 Oct;32(19):2395-404
references.pmid: 21875859
references.citation: Eur Heart J. 2011 Oct;32(20):2507-15
references.pmid: 21875858
references.citation: Eur Heart J. 2012 Jul;33(14):1787-847
references.pmid: 22611136
references.citation: Am J Cardiol. 2015 Dec 15;116(12):1890-7
references.pmid: 26508709
references.citation: Dtsch Med Wochenschr. 2015 Mar;140(5):e48-55
references.pmid: 25734683
references.citation: Arq Bras Cardiol. 2013 May;100(5):390-4
references.pmid: 23740432